Advertisement

pp 1-20 | Cite as

Controversies in Radiotherapy for Hepatocellular Carcinoma

  • Guo-Liang JiangEmail author
  • Zheng Wang
Chapter
Part of the Medical Radiology book series

Abstract

Radiation therapy for liver carcinomas has been used in some hospitals in North America and Europe, but widely in Asia. However, the role of radiation therapy in the management of liver carcinoma has not been recognized in liver cancer society, especially in North America and Europe. The modern radiation techniques, 3-dimensional radiation therapy, intensity-modulated radiation therapy, stereotactic body radiotherapy, and proton and carbon ion beam radiation therapy have yielded very encouraging outcome. Recently, the role of radiation therapy just started to be recognized by NCCN guideline.

In the radiation therapy society, there were controversies regarding the radiation techniques: (1) What was the optimal management to control target motion, especially for beam scanning delivery in proton and carbon ion therapy? (2) What were the optimal radiation fractionation and total dose for hypofractionated or stereotactic body radiation therapy? (3) What were the normal liver tolerances for the livers with different degrees of hepatic cirrhosis, when different irradiation fractionations and total doses were applied? (4) What were the appropriate indications for different radiation techniques?

Keywords

Dose fractionation Moving target Normal liver irradiation tolerance Proton and carbon ion SBRT 

References

  1. Andolino DL, Johnson CS, Maluccio M et al (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81:e447–e453Google Scholar
  2. ASTRO, Model policies, proton beam therapy. May 2014. http://www.astro.org.
  3. Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH (2013) Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci 28:213–219Google Scholar
  4. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.  https://doi.org/10.3322/caac.21492Google Scholar
  5. Bujold A, Massey CA, Kim JJ et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639Google Scholar
  6. Bush DA, Kayali Z, Grove R, Slater JD (2011) The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 117:3053–3059Google Scholar
  7. Chen W, Zheng R, Baade PD et al (2016) CA Cancer J Clin.  https://doi.org/10.3322/caac.21338Google Scholar
  8. Cheng JC, Wu JK, Huang CM et al (2002) Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 54(1):156–162Google Scholar
  9. Chiba T, Tokuuye K, Matsuzaki Y et al (2005) Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 11(10):3799–3805Google Scholar
  10. Chinese Ministry of Health (2011) Practice guideline of the diagnosis and treatment for liver cancer (Practice guideline for the diagnosis and treatment for primary liver cancers). J Clin Hepatol 27(11):1141–1159Google Scholar
  11. Chinese Society of Clinical Oncology (CSCO) guideline of diagnosis and treatment in liver cancers. 2018Google Scholar
  12. Cho YB, Lee KU, Suh KS et al (2007) Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching. J Gastroenterol Hepatol 22:1643–1649Google Scholar
  13. Choi BO, Choi IB, Jang HS et al (2008) Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 8:351Google Scholar
  14. Choi C, Koom WS, Kim TH et al (2014) A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 90(5):1051–1060Google Scholar
  15. Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821Google Scholar
  16. Dewas S, Bibault JE, Mirabel X et al (2012) Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 7:166Google Scholar
  17. Dhir M, Melin AA, Douaiher J et al (2016) A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 263:1112–1125Google Scholar
  18. Dyk P, Weiner A, Badiyan S et al (2015) Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the Child-Pugh score classification system. Pract Radiat Oncol 5(3):176–182Google Scholar
  19. Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122Google Scholar
  20. Gong GZ, Yin Y, Xing LG et al (2012) RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma. Strahlenther Onkol 188(3):262–268Google Scholar
  21. Gu K, Lai ST, Ma NY et al (2011) Hepatic regeneration after sublethal partial liver irradiation in cirrhotic rats. J Radiat Res (Tokyo) 52(5):582–591Google Scholar
  22. Guha C, Kavanagh BD (2011) Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 21:256–263Google Scholar
  23. Guo WJ, Yu EX, Liu LM et al (2003) Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 9(8):1697–1701Google Scholar
  24. Guo WX, Sun JX, Cheng YQ et al (2013) Percutaneous radiofrequency ablation versus partial hepatectomy for small centrally located hepatocellular carcinoma. World J Surg 37:602–607Google Scholar
  25. Hong TS, Wo JY, Yeap BY et al (2015) Multi-institutional Phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol.  https://doi.org/10.1200/JCO.2015.64.2710Google Scholar
  26. Hou JZ, Zeng ZC, Zhang JY et al (2012) Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. Int J Radiat Oncol Biol Phys 84(2):362–368Google Scholar
  27. Hsieh CH, Liu CY, Shueng PW et al (2010) Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma. Radiat Oncol 5:40Google Scholar
  28. Hsu WC, Chan SC, Ting LL et al (2006) Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol 36(2):93–99Google Scholar
  29. Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, Su YF, Fan CY, Chang YW (2012) Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84:355–361Google Scholar
  30. Huo YR, Eslick GD (2015) Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol 1(6):756Google Scholar
  31. Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, Katz A, Goodman K, Stephans K, El-Gazzaz G, Aucejo F, Miller C, Fung J, Lo S, Machtay M, Sanabria JR (2012) Multicenter results of stereotactic body radiotherapy (SBRT) for nonresectable primary liver tumors. Acta Oncol 51:575–583Google Scholar
  32. Ingold JA et al (1965) Radiation hepatitis. Am J Roentgenol Radium Therapy Nucl Med 93:200–208Google Scholar
  33. Jackson A, Ten Haken RK, Robertson JM et al (1995) Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 31:883–891Google Scholar
  34. Jiang W, Zeng ZC (2013) Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncology 84(Suppl 1):69–74Google Scholar
  35. Kagawa T, Koizumi J, Kojima S et al (2010) Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 116:3638–3644Google Scholar
  36. Kang JK, Kim MS, Cho CK et al (2012) Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete trans-arterial chemoembolization. Cancer 118(21):5424–5431Google Scholar
  37. Kasuya G, Kato H, Yasuda S et al (2017) Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer 123(20):3955–3965Google Scholar
  38. Kawashima M, Furuse J, Nishio T et al (2005) Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23:1839–1846Google Scholar
  39. Kim TH, Kim DY, Park JW et al (2006) Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 29(6):568–575Google Scholar
  40. Kim TH, Kim DY, Park J-W et al (2007) Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 67:225–231Google Scholar
  41. Kim SE, Lee HC, Kim KM et al (2011) Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol 17(2):113–119Google Scholar
  42. Kim TH, Park JW, Kim YJ et al (2014) Intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 190(10):882–890Google Scholar
  43. Kim TH, Park JW, Kim YJ et al (2015a) Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 47(1):34–45Google Scholar
  44. Kim GA, Shim JH, Yoon SM et al (2015b) Comparison of chemoembolization with and without radiation therapy and Sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol 26(3):320–329. e6Google Scholar
  45. Klein J, Dawson LA (2013) Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiation Oncol Biol Phys 87(1):22–32Google Scholar
  46. Komatsu S, Fukumoto T, Demizu Y et al (2011) Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 117:4890–4904Google Scholar
  47. Kwon JY, Yoon SK, Chung KW (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10:475Google Scholar
  48. Lasley FD, Mannina EM, Johnson CS et al (2015) Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 5(5):e443–e449Google Scholar
  49. Lazarev S, Hardy-Abeloos C, Factor O et al (2018) Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities. J Cancer Res Clin Oncol 144(10):2077–2083Google Scholar
  50. Liang SX, Zhu XD, Lu HJ et al (2005) Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 103(10):2181–2188Google Scholar
  51. Liang SX, Zhu XD, Xu ZY et al (2006) Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65:426–434Google Scholar
  52. Liu MT, Li SH, Chu TC et al (2004) Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 34(9):532–539Google Scholar
  53. Livraghi T, Brambilla G, Carnaghi C et al (2010) Is it time to reconsider the BCLC/AASLD therapeutic flow-chart? J Surg Oncol 102(7):868–876Google Scholar
  54. Management of hepatocellular carcinoma, European Association for the Study of the Liver (2012) European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 48:599–641Google Scholar
  55. Ministry of Health of the People’s Republic of China (2011) Practice guideline for the diagnosis and treatment for primary liver cancers. J Clin Hepatol 27(11):1141–1159Google Scholar
  56. Mizumoto M, Okumura T, Hashimoto T et al (2011) Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81(4):1039–1045Google Scholar
  57. Mornex F, Girard N, Beziat C et al (2006) Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 66(4):1152–1158Google Scholar
  58. Mulier S, Ni Y, Jamart J et al (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242:158–171Google Scholar
  59. Nakayama H, Sugahara S, Tokita M et al (2009) Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 115:5499–5506Google Scholar
  60. Nishikawa H, Inuzuka T, Takeda H et al (2011) Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 11:143Google Scholar
  61. Ohri N, Tome WA, Mendez Romero A et al (2018) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys.  https://doi.org/10.1016/j.ijrobp.2017.12.288. pii: S0360-3016(17)34525-X
  62. Pan C, Kavanagh B, Dawson L, Li XA, Das S, Miften M, Ten Haken R (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76:S94–S100Google Scholar
  63. Park HC, Seong J, Han KH et al (2002) Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 54(1):150–155Google Scholar
  64. Park W, Lim do H, Paik SW et al (2005) Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 61(4):1143–1150Google Scholar
  65. Qi WQ, Fu S, Zhang Q et al (2015) Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 114:289–295Google Scholar
  66. Ren ZG, Zhao JD, Gu K et al (2011) Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study. Int J Radiat Oncol Biol Phys 79(2):496–502Google Scholar
  67. Ren ZG, Zhao JD, Gu K et al (2012) Hepatic proliferation after partial liver irradiation in rat. Mol Biol Rep 39(4):3829–3836Google Scholar
  68. Santambrogio R, Salceda J, Costa M et al (2013) External validation of a simplified BCLC staging system for early hepatocellular carcinoma. Eur J Surg Oncol 39(8):850–857Google Scholar
  69. Sanuki N, Takeda A, Oku Y et al (2014) Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 53(3):399–404Google Scholar
  70. Seo YS, Kim MS, Yoo SY et al (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:209–214Google Scholar
  71. Seong J, Keum KC, Han KH et al (1999) Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radat Oncol Biol Phys 43(2):393–397Google Scholar
  72. Seong J, Park HC, Han KH et al (2000) Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 47(5):1331–1335Google Scholar
  73. Seong J, Park HC, Han KH, Chon CY (2003) Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 55(2):329–336Google Scholar
  74. Son SH, Kay CS, Song JH et al (2013) Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma. Radiat Oncol 8:11Google Scholar
  75. Song JH, Son SH, Kay CS et al (2015) Reducing the probability of radiation-induced hepatic toxicity by changing the treatment modality from helical tomotherapy to fixed-beam intensity-modulated radiotherapy. Oncotarget 6(32):33952–33960Google Scholar
  76. Su TS, Luo R, Liang P et al (2018. pii: S0360-3016(17)34525-X) A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma [published online January 6, 2018]. Radiother Oncol.  https://doi.org/10.1016/j.ijrobp.2017.12.288
  77. Takeda A, Sanuki N, Eriguchi T et al (2014) Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. Gastroenterol Hepatol 29(2):372–379Google Scholar
  78. Tang QH, Li AJ, Yang GM et al (2013) Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg 37(6):1362–1370Google Scholar
  79. Tsujii H, Kamada T, Shirai T, Noda K, Tsuji H, Karasawa K (eds) (2014) Carbon ion radiotherapy, hepatocellular carcinoma. Springer, Japan, pp 213–220Google Scholar
  80. Velec M, Haddad CR, Craig T et al (2017) Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 97(5):939–946Google Scholar
  81. Verslype C, Rosmorduc O, Rougier P et al (2012) Hepatocellular carcinoma: ESMO–ESDO Clinical Practice. Ann Oncol 23(Suppl 7):vii41–vii48Google Scholar
  82. Wahl DR, Stenmark MH, Tao Y et al (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34(5):452Google Scholar
  83. Wang WW (n.d.), Dosimetric comparison among irradiation plans of photon, proton and carbon ion beams for 8 patients with hepatocellular carcinoma. Chinese JGoogle Scholar
  84. Wang Z, Wang WW, Shahnazi K et al (2018) Carton ion radiation therapy for liver tumors. In: Target volume delineation an treatment planning for particle therapy. A practical guide. Springer International Publishing, Switzerland, pp 221–233Google Scholar
  85. Wu DH, Liu L, Chen LH (2004) Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 10(15):2184–2189Google Scholar
  86. Xu ZY, Liang SX, Zhu J et al (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65:189–195Google Scholar
  87. Yoon SM (2018) JAMA Oncol. onlineGoogle Scholar
  88. Yoon SM, Lim YS, Won HJ et al (2012) Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 82(5):2004–2011Google Scholar
  89. Yoon HI, Lee IJ, Han KH et al (2014) Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 140(9):1595–1605Google Scholar
  90. Zeng ZC, Tang ZY, Fan J et al (2004) A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 10(5):307–316Google Scholar
  91. Zhao JD, Xu ZY, Zhu J et al (2008) Application of active breathing control in 3-dimensional conformal radiation therapy for hepatocellular carcinoma: the feasibility and benefit. Radiother Oncol 87(3):439–444Google Scholar
  92. Zhao JD, Jiang GL, Hu WG et al (2009) Hepatocyte regeneration after partial liver irradiation in rats. Exp Toxicol Pathol 61(5):511–518Google Scholar
  93. Zhao Q, Wang R, Zhu J et al (2016) Superiority of helical tomotherapy on liver sparing and dose escalation in hepatocellular carcinoma: a comparison study of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy. Oncol Targets Ther 9:3807–3813Google Scholar
  94. Zhou ZH, Liu LM, Chen WW et al (2007) Combined therapy of transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 80(951):194–201Google Scholar

Copyright information

© Springer Nature Switzerland AG  2019

Authors and Affiliations

  1. 1.Department of Radiation OncologyShanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer CenterShanghaiChina

Personalised recommendations